BSE filing, NSE: ZENOTECH. Summary written from the filing by ALFA Finder's alert engine.
Zenotech Laboratories Ltd: key numbers
- Share price
- ₹38.54
- Market cap
- ₹235.2 Cr
- Revenue (annual)
- ₹43.61 Cr
- Net profit (annual)
- ₹-1.07 Cr
- P/E (TTM)
- -55.3×Sector 37.9×
- Promoter holding
- 68.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zenotech Laboratories Ltd
All →Zenotech Laboratories Q2 FY27 Results: Net Loss of ₹2.6 Cr, Loss Widens
Zenotech Laboratories Ltd reported revenue from operations of ₹6.1 Cr (-40.2% YoY) and a net loss of ₹2.6 Cr for Q2 FY27.
- Key figure
- Net loss ₹2.6 Cr
Zenotech Laboratories Board Meeting Date
Zenotech Laboratories will hold a board meeting on October 28, 2026, to consider and approve the unaudited financial results for the period ended September 30, 2026.
Zenotech Laboratories Other Announcement
Zenotech Laboratories submitted the Regulation 74(5) compliance certificate for the quarter ended September 30, 2026, confirming dematerialization activities performed by its registrar.
Zenotech Laboratories Annual General Meeting
Zenotech Laboratories Limited concluded its 37th Annual General Meeting. Shareholders approved the adoption of financial statements and re-appointment of Mr. Jignesh Anantray Goradia as Director.
Zenotech Laboratories Annual General Meeting
Zenotech Laboratories Limited will hold its 37th Annual General Meeting on September 25, 2026, via video conferencing. The cut-off date for voting is September 18, 2026.
Zenotech Laboratories Q1 FY27 Results: Net Loss of ₹0.5 Cr
Zenotech Laboratories Ltd reported revenue from operations of ₹9.6 Cr (+11.6% YoY) and a net loss of ₹0.5 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.5 Cr
Other debt & borrowing announcements
All →Brigade Enterprises Debt & Borrowing
Brigade Enterprises' subsidiary Venusta Ventures will issue rated NCDs to IFC under an investment framework agreement. No amount is disclosed in the filing.
Max Estates Debt & Borrowing: ₹350 Cr
Max Estates' board approved a ₹350 crore corporate guarantee for a wholly-owned subsidiary's term loan. Monitoring agency reports on its QIP and warrant proceeds were also filed.
- Value
- ₹350.0 Cr
Credent Connect N Care Debt & Borrowing: ₹4.5 Cr
Credent Connect N Care's board approved an unsecured inter-corporate loan of Rs 4.50 Crore to Kartavya Healtheon Private Limited. The loan carries 12% compounded interest after 25 November 2026 and gives the lender a right to up to 26% equity.
- Value
- ₹4.50 Cr
Amines & Plasticizers Debt & Borrowing
Amines & Plasticizers invited members to place unsecured deposits under Form DPT-1. Only resident members may subscribe, and the scheme is on the company website.
HEG Advanced Materials Debt & Borrowing: ₹50 Cr
HEG granted subsidiary Replus Engitech an unsecured revolving loan of Rs.50 Crore. It is repayable on demand at 9% interest, at arm's length.
- Value
- ₹50.00 Cr
- Execution
- Repayable on demand
Purple Finance Debt & Borrowing: ₹25 Cr
Purple Finance's finance committee approved issuing up to 25,000 senior secured NCDs aggregating ₹25 Crore on a private placement basis. The debentures carry an 11.50% coupon and a 30-month tenure.
- Value
- ₹25.00 Cr
- Execution
- 30 months from deemed date of allotment